In this episode of the ChinaPower Podcast, Dr. Yanzhong Huang joins us to examine China’s growing influence over the global pharmaceutical industry and the risks it poses for the United States. Dr. Huang explains how China evolved from a low-cost manufacturer of chemical inputs to a comprehensive pharmaceutical power producing advanced drugs and playing an important role in global pharmaceutical innovation. He highlights areas of acute U.S. dependence, from antibiotics and vitamins to critical precursor chemicals, and recounts how the Covid-19 pandemic underscored the vulnerability of U.S. supply chains. Dr. Huang explains the highly interdependent nature of global drug supply chains and notes that even if countries attempt to build alternative production capacity outside of China, they would still rely on Chinese suppliers at certain stages of the supply chain and would need years to replicate China’s integrated industrial ecosystems. He concludes with an assessment of U.S. policy options for building resilience, including targeted de-risking of key medicines and diversifying suppliers among trusted partners.  Dr. Yanzhong Huang is a senior fellow for global health at the Council on Foreign Relations, where he directs the Global Health Governance roundtable series. He is also a professor and director of global health studies at Seton Hall University's School of Diplomacy and International Relations, where he developed the first academic concentration among U.S. professional international affairs schools that explicitly addresses the security and foreign policy aspects of health issues. He is the founding editor of Global Health Governance: The Scholarly Journal for the New Health Security Paradigm.  Dr. Huang is the author of multiple books and reports, including most recently The COVID-19 Pandemic and China’s Global Health Leadership, published in 2022.